DE60306904D1 - Selektive dipeptidische inhibitoren von kallikrein - Google Patents

Selektive dipeptidische inhibitoren von kallikrein

Info

Publication number: DE60306904D1
Authority: DE; Germany
Prior art keywords: callicle; dipeptidic; inhibitors; selective; selective dipeptidic
Prior art date: 2002-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60306904T

Other languages

English (en)

Other versions

DE60306904T2 (de

Inventor

David Michael Evans

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vantia Ltd

Original Assignee

Ferring BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-08

Filing date

2003-03-04

Publication date

2006-08-31

2003-03-04 Application filed by Ferring BV filed Critical Ferring BV

2006-08-31 Publication of DE60306904D1 publication Critical patent/DE60306904D1/de

2007-02-08 Application granted granted Critical

2007-02-08 Publication of DE60306904T2 publication Critical patent/DE60306904T2/de

2023-03-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pyridine Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE60306904T 2002-03-08 2003-03-04 Selektive dipeptidische inhibitoren von kallikrein Expired - Lifetime DE60306904T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0205527		2002-03-08
GBGB0205527.5A GB0205527D0 (en)	2002-03-08	2002-03-08	Inhibitors
PCT/GB2003/000908 WO2003076458A2 (en)	2002-03-08	2003-03-04	Selective dipeptide inhibitors of kallikrein

Publications (2)

Publication Number	Publication Date
DE60306904D1 true DE60306904D1 (de)	2006-08-31
DE60306904T2 DE60306904T2 (de)	2007-02-08

Family

ID=9932619

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60306904T Expired - Lifetime DE60306904T2 (de)	2002-03-08	2003-03-04	Selektive dipeptidische inhibitoren von kallikrein

Country Status (26)

Country	Link
US (1)	US7649000B2 (de)
EP (1)	EP1483284B1 (de)
JP (1)	JP4330450B2 (de)
KR (1)	KR100974633B1 (de)
CN (1)	CN1274713C (de)
AR (1)	AR039868A1 (de)
AT (1)	ATE333463T1 (de)
AU (1)	AU2003208471B2 (de)
CA (1)	CA2478099C (de)
DE (1)	DE60306904T2 (de)
DK (1)	DK1483284T3 (de)
EG (1)	EG25482A (de)
ES (1)	ES2264523T3 (de)
GB (1)	GB0205527D0 (de)
IL (2)	IL163710A0 (de)
MX (1)	MXPA04008523A (de)
MY (1)	MY130830A (de)
NO (1)	NO332678B1 (de)
NZ (1)	NZ534891A (de)
PL (1)	PL209670B1 (de)
PT (1)	PT1483284E (de)
RU (1)	RU2301225C2 (de)
TW (1)	TWI283685B (de)
UY (1)	UY27699A1 (de)
WO (1)	WO2003076458A2 (de)
ZA (1)	ZA200406856B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1736465A4 (de)	2004-03-31	2009-06-17	Ajinomoto Kk	Anilinderivative
JP2010536870A (ja) *	2007-08-21	2010-12-02	ジェンザイム・コーポレーション	カリクレイン阻害剤を用いた治療
GB0918924D0 (en) *	2009-10-28	2009-12-16	Vantia Ltd	Azaindole derivatives
US9290485B2 (en)	2010-08-04	2016-03-22	Novartis Ag	N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en)	2011-07-07	2013-03-27	Kalvista Pharmaceuticals Ltd	Plasma kallikrein inhibitors
WO2013111107A1 (en)	2012-01-27	2013-08-01	Novartis Ag	Aminopyridine derivatives as plasma kallikrein inhibitors
US20140378474A1 (en)	2012-01-27	2014-12-25	Novartis Ag	5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
GB201212081D0 (en)	2012-07-06	2012-08-22	Kalvista Pharmaceuticals Ltd	New polymorph
GB201300304D0 (en)	2013-01-08	2013-02-20	Kalvista Pharmaceuticals Ltd	Benzylamine derivatives
IL239682B (en)	2013-01-08	2018-10-31	Kalvista Pharmaceuticals Ltd	History of benzylamine and 2-(aminomethyl)pyridine
GB2510407A (en)	2013-02-04	2014-08-06	Kalvista Pharmaceuticals Ltd	Aqueous suspensions of kallikrein inhibitors for parenteral administration
CA2912285C (en)	2013-05-23	2021-07-13	Kalvista Pharmaceuticals Limited	Fused 6,5 or 6,6-heteroaromatic bicyclic amide derivatives and pharmaceutical compositions thereof useful as plasma kallikrein inhibitor
PL3033336T3 (pl)	2013-08-14	2018-11-30	Kalvista Pharmaceuticals Limited	Inhibitory kalikreiny w plaźmie
GB2517908A (en) *	2013-08-14	2015-03-11	Kalvista Pharmaceuticals Ltd	Bicyclic inhibitors
TWI636047B (zh)	2013-08-14	2018-09-21	英商卡爾維斯塔製藥有限公司	雜環衍生物
WO2015063465A2 (en) *	2013-10-28	2015-05-07	Bicycle Therapeutics Limited	Novel polypeptides
CN108892661B (zh)	2014-02-07	2023-03-14	艾克赛特赫拉制药有限责任公司	治疗化合物和组合物
GB201421088D0 (en)	2014-11-27	2015-01-14	Kalvista Pharmaceuticals Ltd	New enzyme inhibitors
GB201421085D0 (en)	2014-11-27	2015-01-14	Kalvista Pharmaceuticals Ltd	New enzyme inhibitors
GB201421083D0 (en)	2014-11-27	2015-01-14	Kalvista Pharmaceuticals Ltd	Enzyme inhibitors
JP6884801B2 (ja)	2016-05-31	2021-06-09	カルビスタ・ファーマシューティカルズ・リミテッド	血漿カリクレインインヒビターとしてのピラゾール誘導体
GB201609607D0 (en)	2016-06-01	2016-07-13	Kalvista Pharmaceuticals Ltd	Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en)	2016-06-01	2016-07-13	Kalvista Pharmaceuticals Ltd	Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201719881D0 (en)	2017-11-29	2018-01-10	Kalvista Pharmaceuticals Ltd	Solid forms of plasma kallikrein inhibitor and salts thereof
HUE057912T2 (hu)	2017-11-29	2022-06-28	Kalvista Pharmaceuticals Ltd	Plazma kallikrein inhibitort tartalmazó dózisformák
EP3873446A4 (de)	2018-10-30	2022-08-03	Exithera Pharmaceuticals Inc.	Therapeutische verbindungen und zusammensetzungen
GB201910116D0 (en)	2019-07-15	2019-08-28	Kalvista Pharmaceuticals Ltd	Treatments of hereditary angioedema
GB201910125D0 (en)	2019-07-15	2019-08-28	Kalvista Pharmaceuticals Ltd	Treatments of angioedema
WO2021028645A1 (en)	2019-08-09	2021-02-18	Kalvista Pharmaceuticals Limited	Plasma kallikrein inhibitors
GB201918994D0 (en)	2019-12-20	2020-02-05	Kalvista Pharmaceuticals Ltd	Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en)	2019-12-09	2021-08-11	Kalvista Pharmaceuticals Ltd	New polymorphs
WO2021198534A1 (en)	2020-04-04	2021-10-07	Oxurion NV	Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2022079446A1 (en)	2020-10-15	2022-04-21	Kalvista Pharmaceuticals Limited	Treatments of angioedema
US20230381162A1 (en)	2020-10-23	2023-11-30	Kalvista Pharmaceuticals Limited	Treatments of angioedema
JP2024505596A (ja)	2021-02-09	2024-02-06	カルビスタ・ファーマシューティカルズ・リミテッド	遺伝性血管性浮腫の治療
WO2023002219A1 (en)	2021-07-23	2023-01-26	Kalvista Pharmaceuticals Limited	Treatments of hereditary angioedema
WO2023144030A1 (en)	2022-01-31	2023-08-03	Oxurion NV	Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en)	2022-02-04	2023-08-10	Oxurion NV	Biomarker for plasma kallikrein inhibitor therapy response
HRP20241160T1 (hr)	2022-04-27	2024-11-22	Kalvista Pharmaceuticals Limited	Formulacije inhibitora kalikreina u plazmi
EP4673437A1 (de)	2023-02-27	2026-01-07	Kalvista Pharmaceuticals Limited	Neue feste form eines plasmakallikreininhibitors
WO2025153806A1 (en)	2024-01-15	2025-07-24	Kalvista Pharmaceuticals Limited	Methods for determining amidolytic activity
WO2025172693A1 (en)	2024-02-13	2025-08-21	Kalvista Pharmaceuticals Limited	Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en)	2024-02-13	2025-08-21	Kalvista Pharmaceuticals Limited	Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9019558D0 (en) *	1990-09-07	1990-10-24	Szelke Michael	Enzyme inhibitors
AU2882792A (en) *	1991-10-23	1993-05-21	Procter & Gamble Company, The	Tripeptide derivative anti-inflammatory agents
SE9301911D0 (sv) *	1993-06-03	1993-06-03	Ab Astra	New peptide derivatives
GB9318637D0 (en) *	1993-09-08	1993-10-27	Ferring Res Ltd	Enzyme inhibitors

2002
- 2002-03-08 GB GBGB0205527.5A patent/GB0205527D0/en not_active Ceased
2003
- 2003-02-26 TW TW092104061A patent/TWI283685B/zh not_active IP Right Cessation
- 2003-03-03 EG EG2003030209A patent/EG25482A/xx active
- 2003-03-04 IL IL16371003A patent/IL163710A0/xx unknown
- 2003-03-04 EP EP03706759A patent/EP1483284B1/de not_active Expired - Lifetime
- 2003-03-04 US US10/506,535 patent/US7649000B2/en not_active Expired - Lifetime
- 2003-03-04 JP JP2003574673A patent/JP4330450B2/ja not_active Expired - Fee Related
- 2003-03-04 CN CNB038054019A patent/CN1274713C/zh not_active Expired - Fee Related
- 2003-03-04 KR KR1020047013816A patent/KR100974633B1/ko not_active Expired - Fee Related
- 2003-03-04 PL PL372977A patent/PL209670B1/pl unknown
- 2003-03-04 WO PCT/GB2003/000908 patent/WO2003076458A2/en not_active Ceased
- 2003-03-04 MX MXPA04008523A patent/MXPA04008523A/es active IP Right Grant
- 2003-03-04 AT AT03706759T patent/ATE333463T1/de active
- 2003-03-04 CA CA2478099A patent/CA2478099C/en not_active Expired - Lifetime
- 2003-03-04 PT PT03706759T patent/PT1483284E/pt unknown
- 2003-03-04 DE DE60306904T patent/DE60306904T2/de not_active Expired - Lifetime
- 2003-03-04 AU AU2003208471A patent/AU2003208471B2/en not_active Ceased
- 2003-03-04 DK DK03706759T patent/DK1483284T3/da active
- 2003-03-04 RU RU2004126610/04A patent/RU2301225C2/ru not_active IP Right Cessation
- 2003-03-04 ES ES03706759T patent/ES2264523T3/es not_active Expired - Lifetime
- 2003-03-04 NZ NZ534891A patent/NZ534891A/xx not_active IP Right Cessation
- 2003-03-06 UY UY27699A patent/UY27699A1/es not_active Application Discontinuation
- 2003-03-06 AR ARP030100772A patent/AR039868A1/es active IP Right Grant
- 2003-03-07 MY MYPI20030803A patent/MY130830A/en unknown
2004
- 2004-08-24 IL IL163710A patent/IL163710A/en active IP Right Grant
- 2004-08-27 ZA ZA200406856A patent/ZA200406856B/en unknown
- 2004-09-03 NO NO20043695A patent/NO332678B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1639186A (zh)	2005-07-13
EP1483284A2 (de)	2004-12-08
JP4330450B2 (ja)	2009-09-16
IL163710A0 (en)	2005-12-18
CA2478099A1 (en)	2003-09-18
TW200403255A (en)	2004-03-01
TWI283685B (en)	2007-07-11
PL209670B1 (pl)	2011-10-31
EP1483284B1 (de)	2006-07-19
KR100974633B1 (ko)	2010-08-06
AR039868A1 (es)	2005-03-09
ZA200406856B (en)	2005-11-30
NZ534891A (en)	2006-03-31
US7649000B2 (en)	2010-01-19
CA2478099C (en)	2011-10-04
ES2264523T3 (es)	2007-01-01
IL163710A (en)	2010-12-30
US20060052313A1 (en)	2006-03-09
DK1483284T3 (da)	2006-10-16
AU2003208471B2 (en)	2006-09-28
HK1072265A1 (en)	2005-08-19
WO2003076458A3 (en)	2003-11-06
PT1483284E (pt)	2006-11-30
CN1274713C (zh)	2006-09-13
NO332678B1 (no)	2012-12-03
UY27699A1 (es)	2003-10-31
MXPA04008523A (es)	2004-12-06
NO20043695L (no)	2004-10-07
JP2005533750A (ja)	2005-11-10
PL372977A1 (en)	2005-08-08
DE60306904T2 (de)	2007-02-08
AU2003208471A1 (en)	2003-09-22
MY130830A (en)	2007-07-31
KR20040089705A (ko)	2004-10-21
EG25482A (en)	2012-01-15
RU2301225C2 (ru)	2007-06-20
GB0205527D0 (en)	2002-04-24
RU2004126610A (ru)	2005-05-27
WO2003076458A2 (en)	2003-09-18
ATE333463T1 (de)	2006-08-15

Publication	Publication Date	Title
DE60306904D1 (de)	2006-08-31	Selektive dipeptidische inhibitoren von kallikrein
EP1499336A4 (de)	2005-06-01	Proteasehemmer
DE60320933D1 (de)	2008-06-26	Rho-kinase inhibitoren
DE60319430D1 (de)	2008-04-10	R- und fgfr-inhibitoren
DK1699455T3 (da)	2013-08-05	Heterocykliske aspartylproteasehæmmere
NO20034045D0 (no)	2003-09-12	Metallproteinase-inhibitorer
NO20034308L (no)	2003-11-26	Nye tyrokinase-inhibitorer
DK1505963T3 (da)	2011-08-08	Hepatitis C-inhibitorer
DE60234125D1 (de)	2009-12-03	E inhibitoren
IS7792A (is)	2005-04-11	Hýdantóínafleiður og notkun þeirra sem TACE hemla
ATE308544T1 (de)	2005-11-15	N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
DK1534290T3 (da)	2012-04-10	Hidtil ukendte kinasehæmmere
EE200300439A (et)	2003-12-15	Metalloproteinaasi inhibiitorid
DE602004018837D1 (de)	2009-02-12	Ptidase-iv-inhibitoren
DE602005019971D1 (de)	2010-04-29	Inhibitoren von cysteinprotease
ATE304015T1 (de)	2005-09-15	Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
EP1474093A4 (de)	2005-02-16	Granzym-b-hemmer
NO20034032L (no)	2003-11-10	Metallproteinase-inhibitorer
EP1660436A4 (de)	2006-11-22	Cathepsininhibitoren
NO20050563L (no)	2005-01-31	N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon
NO20044269L (no)	2004-10-08	Smamolekylaere inntrengningsinhibitorer
DE60316425D1 (de)	2007-10-31	NF-kappaB-INHIBITOREN
NO20043610L (no)	2004-10-05	Fenylpyrimidinaminer som IgE inhibitorer
DE60331820D1 (de)	2010-05-06	Beseitigung von verstopfungen von rohrleitungen
DE602004014762D1 (de)	2008-08-14	Proteasehemmer

Legal Events

Date	Code	Title	Description
2007-08-09	8364	No opposition during term of opposition
2010-08-19	8327	Change in the person/name/address of the patent owner	Owner name: VANTIA LTD., CHILWORTH, GB
2012-01-16	R082	Change of representative	Ref document number: 1483284 Country of ref document: EP Representative=s name: SCHNEIDERS & BEHRENDT RECHTS- UND PATENTANWAELTE,

Date

Code

Title

Description

2007-08-09

8364

No opposition during term of opposition

2010-08-19

8327

Change in the person/name/address of the patent owner

Owner name: VANTIA LTD., CHILWORTH, GB

2012-01-16

R082

Change of representative

Ref document number: 1483284

Country of ref document: EP

Representative=s name: SCHNEIDERS & BEHRENDT RECHTS- UND PATENTANWAELTE,